Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer

NCT03827473 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped The trial was closed because the changing standard of care landscape, making this trial not impactful anymore.

Conditions

Castration-Sensitive Prostate Carcinoma
Metastatic Prostatic Adenocarcinoma
Stage IV Prostate Cancer
Stage IVA Prostate Cancer
Stage IVB Prostate Cancer

Interventions

DRUG: Abiraterone Acetate
DRUG: Antiandrogen Therapy
DRUG: Docetaxel
DRUG: Prednisone
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration

Sponsor

University of Utah